Pfizer has not yet accrued the32 COVID infections for its 1st interim analysis: The fact that Pfizer’s first interim has not been triggered suggests the participants enrolled in the trial may have lower exposure to COVID-19 compared to the general population and/or reported COVID infections overestimating the rate of symptomatic infections. We adjusted our assumptions on the infection rate in…

This content is for Premium Membership and Contributor Membership members only.
Login Join Now

©2024 Finom Group | Website by: Ocala Website Designs LLC

Log in with your credentials


Forgot your details?

Create Account